Molecular markers for bladder cancer screening, early diagnosis, and surveillance

The WHO/ICUD consensus

Bernd J. Schmitz-Dräger, Michael Droller, Vinata B Lokeshwar, Yair Lotan, M'Liss A. Hudson, Bas W. Van Rhijn, Michael J. Marberger, Yves Fradet, George P. Hemstreet, Per Uno Malmstrom, Osamu Ogawa, Pierre I. Karakiewicz, Shahrokh F. Shariat

Research output: Contribution to journalReview article

63 Citations (Scopus)

Abstract

Due to the lack of disease-specific symptoms, diagnosis and follow-up of bladder cancer has remained a challenge to the urologic community. Cystoscopy, commonly accepted as a gold standard for the detection of bladder cancer, is invasive and relatively expensive, while urine cytology is of limited value specifically in low-grade disease. Over the last decades, numerous molecular assays for the diagnosis of urothelial cancer have been developed and investigated with regard to their clinical use. However, although all of these assays have been shown to have superior sensitivity as compared to urine cytology, none of them has been included in clinical guidelines. The key reason for this situation is that none of the assays has been included into clinical decision-making so far. We reviewed the current status and performance of modern molecular urine tests following systematic analysis of the value and limitations of commercially available assays. Despite considerable advances in recent years, the authors feel that at this stage the added value of molecular markers for the diagnosis of urothelial tumors has not yet been identified. Current data suggest that some of these markers may have the potential to play a role in screening and surveillance of bladder cancer. Well-designed protocols and prospective, controlled trials will be needed to provide the basis to determine whether integration of molecular markers into clinical decision-making will be of value in the future.

Original languageEnglish (US)
Pages (from-to)1-24
Number of pages24
JournalUrologia Internationalis
Volume94
Issue number1
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Early Detection of Cancer
Urinary Bladder Neoplasms
Early Diagnosis
Urine
Cell Biology
Cystoscopy
Neoplasms
Guidelines
Clinical Decision-Making

Keywords

  • Bladder cancer
  • Diagnosis
  • Molecular markers
  • Surveillance
  • Urine

ASJC Scopus subject areas

  • Urology

Cite this

Schmitz-Dräger, B. J., Droller, M., Lokeshwar, V. B., Lotan, Y., Hudson, ML. A., Van Rhijn, B. W., ... Shariat, S. F. (2015). Molecular markers for bladder cancer screening, early diagnosis, and surveillance: The WHO/ICUD consensus. Urologia Internationalis, 94(1), 1-24. https://doi.org/10.1159/000369357

Molecular markers for bladder cancer screening, early diagnosis, and surveillance : The WHO/ICUD consensus. / Schmitz-Dräger, Bernd J.; Droller, Michael; Lokeshwar, Vinata B; Lotan, Yair; Hudson, M'Liss A.; Van Rhijn, Bas W.; Marberger, Michael J.; Fradet, Yves; Hemstreet, George P.; Malmstrom, Per Uno; Ogawa, Osamu; Karakiewicz, Pierre I.; Shariat, Shahrokh F.

In: Urologia Internationalis, Vol. 94, No. 1, 01.01.2015, p. 1-24.

Research output: Contribution to journalReview article

Schmitz-Dräger, BJ, Droller, M, Lokeshwar, VB, Lotan, Y, Hudson, MLA, Van Rhijn, BW, Marberger, MJ, Fradet, Y, Hemstreet, GP, Malmstrom, PU, Ogawa, O, Karakiewicz, PI & Shariat, SF 2015, 'Molecular markers for bladder cancer screening, early diagnosis, and surveillance: The WHO/ICUD consensus', Urologia Internationalis, vol. 94, no. 1, pp. 1-24. https://doi.org/10.1159/000369357
Schmitz-Dräger, Bernd J. ; Droller, Michael ; Lokeshwar, Vinata B ; Lotan, Yair ; Hudson, M'Liss A. ; Van Rhijn, Bas W. ; Marberger, Michael J. ; Fradet, Yves ; Hemstreet, George P. ; Malmstrom, Per Uno ; Ogawa, Osamu ; Karakiewicz, Pierre I. ; Shariat, Shahrokh F. / Molecular markers for bladder cancer screening, early diagnosis, and surveillance : The WHO/ICUD consensus. In: Urologia Internationalis. 2015 ; Vol. 94, No. 1. pp. 1-24.
@article{e69fb04dbf6d405bb8586e068c519dfd,
title = "Molecular markers for bladder cancer screening, early diagnosis, and surveillance: The WHO/ICUD consensus",
abstract = "Due to the lack of disease-specific symptoms, diagnosis and follow-up of bladder cancer has remained a challenge to the urologic community. Cystoscopy, commonly accepted as a gold standard for the detection of bladder cancer, is invasive and relatively expensive, while urine cytology is of limited value specifically in low-grade disease. Over the last decades, numerous molecular assays for the diagnosis of urothelial cancer have been developed and investigated with regard to their clinical use. However, although all of these assays have been shown to have superior sensitivity as compared to urine cytology, none of them has been included in clinical guidelines. The key reason for this situation is that none of the assays has been included into clinical decision-making so far. We reviewed the current status and performance of modern molecular urine tests following systematic analysis of the value and limitations of commercially available assays. Despite considerable advances in recent years, the authors feel that at this stage the added value of molecular markers for the diagnosis of urothelial tumors has not yet been identified. Current data suggest that some of these markers may have the potential to play a role in screening and surveillance of bladder cancer. Well-designed protocols and prospective, controlled trials will be needed to provide the basis to determine whether integration of molecular markers into clinical decision-making will be of value in the future.",
keywords = "Bladder cancer, Diagnosis, Molecular markers, Surveillance, Urine",
author = "Schmitz-Dr{\"a}ger, {Bernd J.} and Michael Droller and Lokeshwar, {Vinata B} and Yair Lotan and Hudson, {M'Liss A.} and {Van Rhijn}, {Bas W.} and Marberger, {Michael J.} and Yves Fradet and Hemstreet, {George P.} and Malmstrom, {Per Uno} and Osamu Ogawa and Karakiewicz, {Pierre I.} and Shariat, {Shahrokh F.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1159/000369357",
language = "English (US)",
volume = "94",
pages = "1--24",
journal = "Urologia Internationalis",
issn = "0042-1138",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Molecular markers for bladder cancer screening, early diagnosis, and surveillance

T2 - The WHO/ICUD consensus

AU - Schmitz-Dräger, Bernd J.

AU - Droller, Michael

AU - Lokeshwar, Vinata B

AU - Lotan, Yair

AU - Hudson, M'Liss A.

AU - Van Rhijn, Bas W.

AU - Marberger, Michael J.

AU - Fradet, Yves

AU - Hemstreet, George P.

AU - Malmstrom, Per Uno

AU - Ogawa, Osamu

AU - Karakiewicz, Pierre I.

AU - Shariat, Shahrokh F.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Due to the lack of disease-specific symptoms, diagnosis and follow-up of bladder cancer has remained a challenge to the urologic community. Cystoscopy, commonly accepted as a gold standard for the detection of bladder cancer, is invasive and relatively expensive, while urine cytology is of limited value specifically in low-grade disease. Over the last decades, numerous molecular assays for the diagnosis of urothelial cancer have been developed and investigated with regard to their clinical use. However, although all of these assays have been shown to have superior sensitivity as compared to urine cytology, none of them has been included in clinical guidelines. The key reason for this situation is that none of the assays has been included into clinical decision-making so far. We reviewed the current status and performance of modern molecular urine tests following systematic analysis of the value and limitations of commercially available assays. Despite considerable advances in recent years, the authors feel that at this stage the added value of molecular markers for the diagnosis of urothelial tumors has not yet been identified. Current data suggest that some of these markers may have the potential to play a role in screening and surveillance of bladder cancer. Well-designed protocols and prospective, controlled trials will be needed to provide the basis to determine whether integration of molecular markers into clinical decision-making will be of value in the future.

AB - Due to the lack of disease-specific symptoms, diagnosis and follow-up of bladder cancer has remained a challenge to the urologic community. Cystoscopy, commonly accepted as a gold standard for the detection of bladder cancer, is invasive and relatively expensive, while urine cytology is of limited value specifically in low-grade disease. Over the last decades, numerous molecular assays for the diagnosis of urothelial cancer have been developed and investigated with regard to their clinical use. However, although all of these assays have been shown to have superior sensitivity as compared to urine cytology, none of them has been included in clinical guidelines. The key reason for this situation is that none of the assays has been included into clinical decision-making so far. We reviewed the current status and performance of modern molecular urine tests following systematic analysis of the value and limitations of commercially available assays. Despite considerable advances in recent years, the authors feel that at this stage the added value of molecular markers for the diagnosis of urothelial tumors has not yet been identified. Current data suggest that some of these markers may have the potential to play a role in screening and surveillance of bladder cancer. Well-designed protocols and prospective, controlled trials will be needed to provide the basis to determine whether integration of molecular markers into clinical decision-making will be of value in the future.

KW - Bladder cancer

KW - Diagnosis

KW - Molecular markers

KW - Surveillance

KW - Urine

UR - http://www.scopus.com/inward/record.url?scp=84923574285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923574285&partnerID=8YFLogxK

U2 - 10.1159/000369357

DO - 10.1159/000369357

M3 - Review article

VL - 94

SP - 1

EP - 24

JO - Urologia Internationalis

JF - Urologia Internationalis

SN - 0042-1138

IS - 1

ER -